FGFR1 and acute lymphoblastic leukemia: Dovitinib is an orally active small molecule targeting tyrosine kinases including FGFR1/3, VEGFR1-4, FLT-3, and c-KIT [48], and is particularly effective in decreasing growth of various T-ALL cell lines.